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Introduction
Daptomycin is a cyclic lipopeptide antibiotic with
activity against many gram-positive organisms,
including strains of staphylococci and enterococci
that are not susceptible to other commonly used
antibiotics, such as penicillinase-resistant penicillins,
vancomycin, linezolid and quinupristin-dalfopristin
(1–7). Daptomycin is rapidly bactericidal, more so
than other antibacterial agents in in vitro time-kill
studies and in vivo animal models (4,6,8,9).
Unlike vancomycin or b-lactam agents, the
bactericidal activity of daptomycin does not result
in immediate cell lysis (10). As bacterial cell lysis
may result in the release of pro-inﬂammatory
bacterial components, lack of bacteriolysis may be
associated with attenuated host inﬂammatory
responses. In an in vitro model, exposure of
Staphylococcus aureus to daptomycin led to an
attenuated macrophage inﬂammatory response
compared with vancomycin or oxacillin (11).
Similarly, in an animal model of pneumococcal
meningitis, daptomycin caused less cerebrospinal
ﬂuid inﬂammation and resulting cortical brain
damage than ceftriaxone (12).
Daptomycin is safe and effective for the treat-
ment of complicated skin and skin structure infec-
tions (cSSSI) (13). Post hoc and subset analyses of
data from two phase 3 trials suggest that daptomy-
cin may result in faster clinical improvement and a
shorter duration of therapy compared with treat-
ment with penicillinase-resistant penicillins or
vancomycin (13,14). A subsequent study of patients
with cSSSI also found that daptomycin resulted in
faster clinical improvement, shorter duration of
intravenous (i.v.) antibiotic therapy, shorter antibi-
otic-associated length of hospital stay and decreased
total hospital costs compared with matched con-
trols treated with vancomycin (15). Based on these
ﬁndings and the unique mechanism of action of
daptomycin, an exploratory clinical trial was con-
ducted to evaluate whether the treatment of celluli-
tis or erysipelas with daptomycin would result in
faster resolution of symptoms and signs compared
with treatment with vancomycin among hospita-
lised patients.
SUMMARY
Background: Results from previous trials suggest that daptomycin may result in
faster clinical improvement than penicillinase-resistant penicillins or vancomycin for
patients with complicated skin and skin structure infections. Objective: The objec-
tive was to evaluate whether daptomycin treatment of cellulitis or erysipelas would
result in faster resolution compared with vancomycin. Design: The study was a
prospective, evaluator-blinded, multi-centre trial. Patients were randomised to
receive daptomycin 4 mg⁄kg once daily or vancomycin according to standard of
care for 7–14 days. Patients: Adults diagnosed with cellulitis or erysipelas requir-
ing hospitalisation and intravenous antibiotic therapy were eligible for enrolment.
Results: The clinical success rates were 94.0% for daptomycin and 90.2% for
vancomycin (95% conﬁdence interval for the difference, )6.7%, 14.3%). There
were no statistically signiﬁcant differences between treatment arms in the time to
resolution or improvement in any of the predeﬁned clinical end-points. Both dapto-
mycin and vancomycin were well tolerated. Conclusions: There was no difference
in the rate of resolution of cellulitis or erysipelas among patients treated with dap-
tomycin or vancomycin. Daptomycin 4 mg⁄kg once daily appeared to be effective
and safe for treating cellulitis or erysipelas.
What’s known
• Daptomycin is safe and effective for the
treatment of complicated skin and skin structure
infections.
• Based on the previous clinical ﬁndings and its
unique mechanism of action, it was thought that
daptomycin might result in faster clinical
improvement than vancomycin for the treatment
of cellulitis and erysipelas.
What’s new
• This study evaluated daptomycin speciﬁcally for
the treatment of cellulitis and erysipelas, and
daptomycin demonstrated safety and efﬁcacy
comparable to that of vancomycin. Daptomycin
and vancomycin were compared with respect to
time to resolution or improvement of symptoms
and signs of infection, with no signiﬁcant
differences detected between treatments.
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Study design
Study DAP-4CELL-05-02 was a prospective, rando-
mised, evaluator-blinded, multi-centre trial designed
to explore differences in the speed and degree of
symptom and sign resolution between daptomycin-
and vancomycin-treated patients with cellulitis or
erysipelas. The study was conducted at 15 sites in the
United States, South Africa and Serbia, in accordance
with the Declaration of Helsinki and guidelines for
studies involving human subjects. Local ethics com-
mittees or institutional review boards approved the
study protocol, and all subjects provided written
informed consent.
Patient eligibility
Patients ‡ 18 years of age who had a primary
diagnosis of cellulitis or erysipelas requiring
hospitalisation and i.v. antibiotic therapy were
eligible for enrolment. The onset of symptoms and
signs must have occurred within 3 days of the
ﬁrst dose of study medication, and a temperature
> 37.5  C orally or > 38.0  C rectally had to be
recorded within 48 h before enrolment. The
infection had to be at an anatomical location
that allowed for clear assessment of the erythema
margin.
Patients were excluded from the study if they
required emergent surgical intervention, if surgery
constituted curative treatment, or if the cellulitis
was associated with a wound or ulcer that required
incision, drainage or debridement. Other excluding
conditions included perirectal abscess; hidradenitis
suppurativa; third-degree burn infections; buccal,
facial, periorbital or perianal cellulitis; known or
suspected osteomyelitis or bacteremia; absolute
neutrophil count £ 500 cells⁄mm
3; creatinine clear-
ance < 30 ml⁄min; rhabdomyolysis; or known
allergy or intolerance to study medications. Patients
were also excluded if they required systemic corti-
costeroids or antibiotics other than the study drugs
or if they had received systemic antimicrobial ther-
apy for > 24 h during the 72 h before the ﬁrst
dose of study drug, unless they had been on the
antimicrobial for ‡ 72 h without clinical improve-
ment. Pregnant or lactating women were excluded.
Treatment
Patients were randomised to receive daptomycin or
vancomycin for 7–14 days. Randomisation was strati-
ﬁed by the presence or absence of four complicating
factors [diabetes mellitus, age ‡ 65 years, peripheral
vascular disease (PVD), or an immunocompromising
condition such as HIV]. Daptomycin was adminis-
tered at 4 mg⁄kg i.v. once daily, and vancomycin
was administered i.v. according to standard of
care. At the discretion of the investigator, aztreonam
and metronidazole could have been added for con-
ﬁrmed or probable infections with gram-negative
aerobic and anaerobic pathogens, respectively.
Administration of anti-inﬂammatory or antipyretic
agents, excluding systemic corticosteroids, was
permitted.
Clinical assessments
The following efﬁcacy end-points were assessed:
(i) time to stabilisation of cellulitis (when the
erythema margin stopped advancing, temperature
normalised and patient was ready for discharge);
(ii) time to cessation of erythema margin advance-
ment; (iii) Time to defervescence (temperature
£ 37.2  C); (iv) time to readiness for hospital dis-
charge (if the patient remained hospitalised for
reasons unrelated to the cellulitis, the patient was
considered ready for discharge); (v) investigator
assessment of symptoms and signs (based on a
composite score of three symptoms – tenderness,
chills and warmth – and the presence of one of
the following signs – lymphangitis, regional lymph-
adenopathy or lymphedema; the maximum possible
score was 13 points); (vi) patient-reported celluli-
tis-related pain (assessed on an analogue scale) and
(vii) patient-reported swelling⁄tightness (assessed
on an analogue scale). Erythema margin size, as
well as symptoms and signs, were assessed by an
evaluator who was unaware of the study drug
assignment. Patients were also evaluated for adverse
events. Baseline assessments were conducted within
3 days before the start of treatment. Evaluations
were conducted three times per day, while patients
were receiving study medication and then
7–14 days after the last dose of study drug. Clinical
success was deﬁned as a patient cured or
improved.
Statistical analysis
All patients who received at least one dose of study
medication were included in the analyses. Data from
patients who discontinued from the study prema-
turely were censored as of the last available evalua-
tion. A physician blinded to study drug assignment
reviewed concomitant medications and procedures
received by each patient; if these were believed to
have inﬂuenced the clinical outcome, the outcome
was censored from the date of the procedure or
medication administration.
This was a non-powered exploratory study.
Kaplan–Meier curves were generated for describing
the distribution of time to each end-point. Log-rank
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rates, 95% conﬁdence intervals for the differences in
rates were calculated between the daptomycin and
vancomycin arms, using normal approximations to
the binomial distribution.
Supporting data
A post hoc analysis was also conducted using
pooled data from two previously reported phase 3
cSSSI trials (13). These were randomised, evalua-
tor-blinded trials that compared the efﬁcacy and
safety of daptomycin with that of conventional
therapy (penicillinase-resistant penicillins or vanco-
mycin). In these trials, infections were classiﬁed
into ﬁve categories: wound infection, major abscess,
infected diabetic ulcer, infected non-diabetic ulcer
and other infection. From the other infection cate-
gory, cases of cellulitis were identiﬁed based on the
description provided by the study investigator.
Clinical and microbiological success rates were cal-
culated, with clinical success deﬁned as clinical
cure or improvement, and microbiological success
deﬁned as pathogen eradication or presumed eradi-
cation based on cultures of the infected site and
blood.
Results
Patients
A total of 103 patients were randomised in the cellu-
litis⁄erysipelas study. One patient in each group did
not receive study drug; thus, the evaluation popula-
tion included 101 patients, 50 treated with daptomy-
cin and 51 with vancomycin. An additional 50
cellulitis patients were identiﬁed from the previous
phase 3 cSSSI trials, 28 treated with daptomycin and
22 with comparator.
Table 1 summarises the demographic and baseline
characteristics of the patients. In the cellulitis⁄erysipe-
las study, 68.3% of patients had at least one of the four
complicating factors. In the two cSSSI studies, 56.0%
of patients had at least one of these four complicating
factors. However, all patients in the cSSSI studies had
complicated infections, deﬁned as the presence of
these or other complicating factors or based upon the
severity and extent of the infection. In contrast, not all
patients in the cellulitis study had complicated infec-
tions, although all were hospitalised. Daptomycin-
treated patients in both the cellulitis and cSSSI studies
tended to have a higher incidence of diabetes and
PVD, and a greater number were ‡ 65 years old.
Table 1 Demographic and baseline patient characteristics in the cellulitis⁄erysipelas and cellulitis subset of the cSSSI
studies
Cellulitis⁄erysipelas study cSSSI studies (cellulitis subset)
Daptomycin
(n = 50), n (%)
Vancomycin
(n = 51), n (%)
Daptomycin
(n = 28), n (%)
Comparator
(n = 22), n (%)
Gender
Female 33 (66.0) 26 (51.0) 12 (42.9) 11 (50.0)
Male 17 (34.0) 25 (49.0) 16 (57.1) 11 (50.0)
Age, median years (range) 57 (22–79) 55 (21–86) 54 (25–79) 48 (18–86)
Race
White 40 (80.0) 36 (70.6) 14 (50.0) 8 (36.4)
Black 7 (14.0) 12 (23.5) 4 (14.3) 9 (40.9)
Other 3 (6.0) 3 (5.9) 10 (35.7) 5 (22.7)
Body mass index, median kg⁄m
2 (range) 32 (20–82) 31 (18–55) 29 (18–62)* 26 (18–51)
Site of infection
Leg 40 (80.0) 38 (74.5) 23 (82.1) 18 (81.8)
Arm 5 (10.0) 4 (7.8) 3 (10.7) 2 (9.1)
Other 5 (10.0) 9 (17.6) 2 (7.1) 2 (9.1)
Presence of speciﬁc complicating factors
Diabetes 15 (30.0) 11 (21.6) 8 (28.6) 5 (22.7)
Age ‡ 65 years 14 (28.0) 13 (25.5) 9 (32.1) 4 (18.2)
Peripheral vascular disease 14 (28.0) 8 (15.7) 9 (32.1) 4 (18.2)
Immunocompromised condition 0 (0.00) 1 (2.0) 2 (7.1) 3 (13.6)
*Twenty-seven patients had baseline body mass index values. Twenty-one patients had baseline body mass index values. All patients
in the cSSSI studies had complicated infections; only the complicating factors reported in the cellulitis⁄erysipelas study are shown for
the patients with cellulitis in the cSSSI studies. cSSSI, complicated skin and skin structure infections.
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mycin- and 35.3% of vancomycin-treated patients
had a previous episode of cellulitis or erysipelas
within the past 5 years. The median time from onset
of the current infection to the ﬁrst dose of study
drug was 2 days (range: 0–8 days) in both treatment
groups. Anti-inﬂammatory drugs were administered
to 28.0% (14⁄50) and 29.4% (15⁄51) of daptomycin-
and vancomycin-treated patients, respectively. One
daptomycin-treated patient received at least 1 day of
topical steroid treatment for the infection and one
vancomycin-treated patient received at least 4 days
of systemic steroid therapy.
A description of baseline symptoms and signs
from the cellulitis⁄erysipelas study is provided in
Table 2. Symptoms and signs were generally similar
between treatment arms, but daptomycin-treated
patients had a lower pain score. A similar proportion
of patients received concomitant medications or
underwent procedures that could have inﬂuenced
outcomes. At least one dose of a systemic antibiotic
other than the assigned study medication was
received by 44.0% of daptomycin- and 51.0% of
vancomycin-treated patients. One patient (2.0%) in
the daptomycin group and three patients (5.9%) in
the vancomycin group underwent incision and drain-
age procedures.
Clinical efﬁcacy
As shown in Table 3, the clinical success rates in the
cellulitis⁄erysipelas study were similar for daptomy-
cin-treated (94.0%) and vancomycin-treated patients
(90.2%). Of the 50 patients in the daptomycin
group, 36 (72.0%) were assessed as cured, 11
(22.0%) were improved and three (6.0%) had no fol-
low-up data. Of the 51 patients in the vancomycin
group, 28 (54.9%) were assessed as cured, 18
(35.3%) were improved, one (2.0%) had worsened
and four (7.8%) had no follow-up data. Among the
patients with cellulitis in the cSSSI studies, clinical
success rates were also similar for daptomycin-treated
(78.6%) and comparator-treated patients (72.7%).
The mean durations of study drug administration
were 6.1 days for daptomycin- and 6.2 days for
vancomycin-treated patients (p = 0.847). There were
no signiﬁcant differences between treatments in the
time to achievement of any of the predeﬁned end-
points in the cellulitis⁄erysipelas study. The median
time to stabilisation of infection was similar for dap-
tomycin and vancomycin (log-rank p = 0.875; 86.5
vs. 85.5 h). Similarly, no differences were observed
between daptomycin- and vancomycin-treated
patients in the median time to defervescence
(p = 0.690; 12.4 vs. 16.3 h), cessation of erythema
advancement (p = 0.833; 21.0 vs. 22.0 h), or readiness
Table 2 Baseline signs and symptoms in the cellulitis⁄erysipelas study
Cellulitis⁄erysipelas study
Daptomycin (n = 50) Vancomycin (n = 51)
Temperature, median degrees celsius (range) 37.4 (35.3–39.8)* 37.2 (35.6–39.2)
Symptoms and signs composite score, median (range) 6 (1–13)§ 6 (1–12)§
Patient-reported pain score, median (range)– 45.5 (1.0–100.0)** 73.0 (0.0–100.0)
Patient-reported tightness⁄swelling score, median (range)– 63.0 (1.0–100.0) 70.0 (2.0–100.0)
*Forty-seven patients had baseline temperatures. Fifty patients had baseline temperatures. Possible scores ranged from zero to 13,
with higher scores indicating more severe symptoms and signs. §Forty-eight patients had baseline symptoms and signs composite
scores. –Based on visual analogue scale from zero (none) to 100 (worst possible). **Forty-six patients had baseline pain scores.
Forty-ﬁve patients had baseline tightness⁄swelling scores.
Table 3 Clinical success rates in the cellulitis⁄erysipelas and cellulitis subset of the cSSSI studies
Daptomycin, n (%) Comparator, n (%) 95% CI*
Cellulitis⁄erysipelas study 47⁄50 (94.0) 46⁄51 (90.2) )6.7, 14.3
cSSSIs studies (cellulitis subset) 22⁄28 (78.6) 16⁄22 (72.7) )18.2, 29.9
*95% conﬁdence interval for the difference in success rates (daptomycin ) comparator). Evaluated 7–14 days after last dose of study
medication. Evaluated 6–20 days after last dose of study medication. cSSSI, complicated skin and skin structure infections.
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addition, no differences were seen between the
groups in the median time to 50% improvement for
investigator-assessed composite scores (p = 0.755;
39.9 vs. 41.2 h) as well as patient-reported pain
(p = 0.632; 37.3 vs. 40.0 h) or tightness⁄swelling
scores (p = 0.307; 31.0 vs. 31.5 h). Similar results
were noted for all endpoints among patients who
received no anti-inﬂammatory drugs (data not
shown).
Microbiological efﬁcacy
Culture data were available for patients enrolled in
the cSSSI studies (Table 4). The most common
organism isolated in both groups was S. aureus,
including both methicillin-susceptible and methicil-
lin-resistant strains. All pathogens were susceptible to
daptomycin and vancomycin. The minimum inhibi-
tory concentration (MIC) of daptomycin that inhib-
ited growth of 90% of baseline S. aureus isolates
(MIC90) was 0.25 lg⁄ml (range: 0.12–0.5 lg⁄ml).
For baseline isolates of Streptococcus pyogenes, the
daptomycin MIC90 was 0.06 lg⁄ml (range: £ 0.03–
0.06 lg⁄ml). For vancomycin, the MIC90 values were
1.0 lg⁄ml (range: 0.5–1.0 lg⁄ml) for S. aureus and
0.25 lg⁄ml (range: 0.25–0.25 lg⁄ml) for S. pyogenes.
For those patients with baseline pathogens, micro-
biological success rates were 72.7% (16⁄22) and
50.0% (7⁄14) for daptomycin- and comparator-trea-
ted patients, respectively (95% CI for the difference:
)9.4% to 54.9%). Two daptomycin- and two com-
parator-treated patients had positive blood cultures
at baseline; one from each group was treated success-
fully. Table 4 shows organism-speciﬁc success rates
for patients with cellulitis in the cSSSI trials.
Safety
In the cellulitis⁄erysipelas study, eight patients in each
treatment group (16.0% of daptomycin- and 15.7% of
vancomycin-treated patients) experienced ‡ 1 treat-
ment-emergent adverse event. Events reported in ‡ 2
patients in either treatment arm included headache
(three daptomycin-treated patients), nausea (two dap-
tomycin-treated patients) and peripheral oedema (two
vancomycin-treated patients). Adverse events that
were possibly or probably related to the study medica-
tion were experienced by three patients in the dapto-
mycin group (one patient had ﬂushing, rash and
dizziness; one had nausea; and one had diarrhoea)
and one patient in the vancomycin group (red man
syndrome). The only patient who discontinued study
drug because of an adverse event was the vancomycin-
treated patient who developed red man syndrome.
Serious adverse events were experienced by one
patient in each group; one daptomycin-treated patient
developed nausea, vomiting and pneumonia, while
one vancomycin-treated patient developed hypoglyca-
emia. None of the serious adverse events was assessed
as related to study drug. No patient had an elevated
creatine phosphokinase (CPK) assessed as an adverse
event. No patient died.
Among the patients with cellulitis in the cSSSI
studies, the frequency and distribution of adverse
events were similar to those reported for all patients
in the trials (13). The most common adverse events
were constipation (two daptomycin- and three com-
parator-treated patients), headache (three daptomy-
cin- and one comparator-treated patients), increased
CPK (three daptomycin- and one comparator-treated
patients), nausea (two daptomycin- and two compar-
ator-treated patients) and insomnia (two daptomy-
cin- and two comparator-treated patients). Four
patients (two in each treatment arm) had treatment-
emergent CPK values > 2 times the upper limit of
normal (ULN). Both CPK elevations noted in the
daptomycin-treated patients, as well as another eleva-
tion that was 1.8 times ULN, were assessed as adverse
events. The highest CPK value in the daptomycin
arm was 1420 U⁄L (ULN = 270 U⁄L). Both compar-
ator-treated patients had CPK elevations on the ﬁrst
day of study drug that resolved and then subsequently
recurred 12 and 21 days after completing therapy.
One of these subsequent CPK elevations was assessed
as an adverse event, while the other was not.
Discussion
Staphylococcus aureus is a common cause of skin and
skin-structure infections (13,16). Hospitalisations in
the USA because of S. aureus-related infections,
including cellulitis, as well as the proportion of these
Table 4 Microbiological success* rates in the cellulitis
subset of the cSSSI studies
Organism
Daptomycin
n (%)
Comparator
n (%)
Staphylococcus aureus 11⁄15 (73.3) 6⁄11 (54.5)
Methicillin-susceptible 10⁄12 (83.3) 3⁄6 (50.0)
Methicillin-resistant 1⁄3 (33.3) 1⁄2 (50.0)
Streptococcus pyogenes 5⁄6 (83.3) 4⁄5 (80.0)
Enterococcus faecalis 2⁄3 (66.7) 1⁄1 (100.0)
Streptococcus agalactiae 2⁄3 (66.7) 0⁄1 (0.0)
Streptococcus
dysgalactiae equisimilis
00 ⁄1 (0.0)
*Microbiological success deﬁned as eradication and presumed
eradication. Six patients in each treatment group had two
organisms isolated at baseline. cSSSI, complicated skin and
skin structure infections.
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increased dramatically (17). In addition, one study
has found that community-associated methicillin-
resistant S. aureus (MRSA) was the most common
organism isolated from patients with purulent skin
and skin structure infections presenting to emergency
departments in the USA (18). The increasing inci-
dence of infections caused by MRSA has signiﬁcant
implications for treatment. Inadequate therapy for
MRSA has been shown to be common in community
hospitals and has been associated with increased
mortality (19).
However, MRSA susceptibility to vancomycin is
decreasing (20–22), and infections caused by vanco-
mycin-susceptible MRSA strains with MIC values
‡ 1 lg⁄ml appear to respond less well to vancomycin
therapy (23–27), even after controlling for patient
variables and comorbidities (28). In addition, clinical
cases of antibiotic-resistant S. aureus have been
reported for newer drugs such as linezolid (29–32),
and one study suggests linezolid MIC values are
increasing (22). Although there have been reports of
resistance to daptomycin, recent surveillance studies
in Europe and North America have demonstrated
‡ 99.9% susceptibility among 20,047 isolates of S. aureus
as well as no increases in MIC values (1–3,22).
In the prospective cellulitis⁄erysipelas trial pre-
sented here, the clinical success rate for daptomycin
was 94.0% vs. 90.2% for vancomycin. Among patients
with cellulitis in the two phase 3 cSSSI studies, the
rates were 78.6% and 72.7% for daptomycin- and
comparator-treated patients, respectively. Although
success rates were lower in the two cSSSI studies, this
is most likely because of the entry criteria for the
cSSSI studies, which selected for complicated infec-
tions. In both the cellulitis⁄erysipelas study and the
cSSSI studies, the efﬁcacy of daptomycin was similar
to and actually slightly better than that of the com-
parators, although the differences were not statisti-
cally signiﬁcant. This is despite daptomycin-treated
patients in the cellulitis⁄erysipelas study having
slightly more complicating underlying diseases.
For patients with cellulitis in the cSSSI studies,
daptomycin achieved good eradication rates against
both S. aureus and S. pyogenes. The microbiological
success rate was higher for daptomycin-treated
patients than for those treated with the comparator
agents, although the difference was not statistically
signiﬁcant. The observed clinical and microbiological
efﬁcacies support the recommendation that dapto-
mycin is an appropriate option for severe skin infec-
tions, such as cellulitis, that require hospitalisation
or do not respond to other treatment (33).
As the rapid bactericidal activity of daptomycin
does not result in immediate cell lysis and because
earlier clinical data suggested that daptomycin may
result in faster resolution of complicated skin infec-
tions (10,13–15), it was anticipated that daptomycin
might result in faster resolution of symptoms and
signs than vancomycin. However, this study was
unable to detect a difference in the time to resolu-
tion of various cellulitis-associated symptoms and
signs or readiness for hospital discharge. It is possible
that the cellulitis⁄erysipelas trial was inadequately
powered to detect differences in the speed of symp-
tom resolution. Alternatively, the methods used to
evaluate the end-points may have been too insensi-
tive to detect differences between treatments.
Daptomycin was well tolerated. The incidence and
distribution of adverse events were similar between
daptomycin- and comparator-treated patients. Head-
ache and nausea were the most common adverse
events among daptomycin-treated patients. This
safety proﬁle for daptomycin is consistent with previ-
ous studies (13,34). In conclusion, daptomycin
4m g⁄kg once daily is effective and safe for treating
cellulitis or erysipelas.
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